0 286

Cited 15 times in

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

DC Field Value Language
dc.contributor.author노재경-
dc.contributor.author라선영-
dc.contributor.author유내춘-
dc.contributor.author정현철-
dc.date.accessioned2020-07-02T17:15:31Z-
dc.date.available2020-07-02T17:15:31Z-
dc.date.issued1998-
dc.identifier.issn0167-6806-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/176699-
dc.description.abstractThe plasma urokinase-type plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), and urokinase-type plasminogen activator receptor (uPAR) levels were measured in healthy volunteers and breast cancer patients. In pre-menopause healthy females, blood was sampled weekly during one menstruation cycle and menstruation phases (follicular, ovulatory, luteal) were determined by FSH/LH levels. uPA, PAI-1, and uPAR levels were at the nadir during ovulatory phase. uPA level was highest at follicular phase while PAI-1 level was highest at luteal phase. In comparison between pre- and post-menopause states, uPA and uPAR levels were higher in post-menopause state while PAI-1 level was higher in pre-menopause state. In breast cancer patients, uPA, PAI-1, and uPAR positive rates were low when we use the menopause-state-unmatched cut-off points. As we adjusted the cut-off points by menopause states, the PAI-1 positivity increased mainly in post-menopause cancer patients. These findings suggest that there is a minor but possible sequential change of these molecules during menstruation cycle which might blur the pathological positivity in pre-menopause cancer patients. The pathological elevation of PAI-1 was well detected in post-menopause cancer patients, but this elevation did not correlate with tumor burden such as number of metastatic sites or metastatic location. In conclusion, adjustment of physiological changes of uPA, PAI-1, and uPAR is required in determining pathological elevation of the plasma levels in cancer patients, especially in females.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherKluwer Academic-
dc.relation.isPartOfBREAST CANCER RESEARCH AND TREATMENT-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdult-
dc.subject.MESHBreast Neoplasms/blood*-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMenstrual Cycle/blood-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPlasminogen Activator Inhibitor 1/blood*-
dc.subject.MESHReceptors, Cell Surface/blood*-
dc.subject.MESHReceptors, Urokinase Plasminogen Activator-
dc.subject.MESHUrokinase-Type Plasminogen Activator/blood*-
dc.titlePhysiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorHyun Cheol Chung-
dc.contributor.googleauthorSun Young Rha-
dc.contributor.googleauthorJoon Oh Park-
dc.contributor.googleauthorNae Choon Yoo-
dc.contributor.googleauthorJoo Hang Kim-
dc.contributor.googleauthorJae Kyung Roh-
dc.contributor.googleauthorJin Sik Min-
dc.contributor.googleauthorKyong Sik Lee-
dc.contributor.googleauthorByung Soo Kim-
dc.contributor.googleauthorJin Ju Kim-
dc.identifier.doi10.1023/a:1005997421733-
dc.contributor.localIdA01290-
dc.contributor.localIdA01316-
dc.contributor.localIdA02457-
dc.contributor.localIdA03773-
dc.relation.journalcodeJ00403-
dc.identifier.eissn1573-7217-
dc.identifier.pmid9694610-
dc.identifier.urlhttps://link.springer.com/article/10.1023/a%3A1005997421733-
dc.contributor.alternativeNameRoh, Jae Kyung-
dc.contributor.affiliatedAuthor노재경-
dc.contributor.affiliatedAuthor라선영-
dc.contributor.affiliatedAuthor유내춘-
dc.contributor.affiliatedAuthor정현철-
dc.citation.volume49-
dc.citation.number1-
dc.citation.startPage41-
dc.citation.endPage50-
dc.identifier.bibliographicCitationBREAST CANCER RESEARCH AND TREATMENT, Vol.49(1) : 41-50, 1998-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.